DESTINY: CML Patients With Stable Molecular Responses Safely Halved TKI Dose

December 05, 2016 | ASH 2016, Chronic Myeloid Leukemia

DESTINY: CML Patients With Stable Molecular Responses Safely Halved TKI Dose
Many patients with stable chronic myeloid leukemia (CML) may be able to safely decrease their dose of tyrosine kinase inhibitor (TKI) to half of the standard dose and improve TKI-related side effects, according to the results of the DESTINY trial (abstract 938) presented at the American Society of Hematology (ASH) 58th Annual Meeting and Exposition, held December 3–6 in San Diego, California.
Because many patients with CML are advised to stay on TKIs indefinitely, there has been an increasing amount of research examining whether or not it would be feasible to discontinue use of TKIs in patients with consistently negative leukemia tests. The DESTINY trial, presented by Mhairi Copland, MD, PhD, of the University of Glasgow, United Kingdom, focused not only on patients with major molecular response (BCR-ABL < 0.01%; MR4 disease), but also included some patients with a stable molecular remission level (BCR-ABL < 0.1%; MR3 disease).

Read more...